IDEAS home Printed from https://ideas.repec.org/a/spr/aphecp/v6y2008i4p231-246.html
   My bibliography  Save this article

Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B

Author

Listed:
  • Elizabeth Arnold
  • Yong Yuan
  • Uchenna Iloeje
  • Greg Cook

Abstract

The availability of entecavir in Australian clinical practice should make long-term suppression of hepatitis B virus replication increasingly attainable, resulting in fewer CHB sequelae, at an acceptable financial cost. Copyright Adis Data Information BV 2008

Suggested Citation

  • Elizabeth Arnold & Yong Yuan & Uchenna Iloeje & Greg Cook, 2008. "Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B," Applied Health Economics and Health Policy, Springer, vol. 6(4), pages 231-246, October.
    • Handle: RePEc:spr:aphecp:v:6:y:2008:i:4:p:231-246
    DOI: 10.1007/BF03256136
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/BF03256136
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/BF03256136?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Isabelle Durand-Zaleski & Stéphane Zaleski, 1994. "DEALE-ing and Discounting," Medical Decision Making, , vol. 14(1), pages 98-103, February.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Peter Wigfield & Urbano Sbarigia & Mahmoud Hashim & Talitha Vincken & Bart Heeg, 2020. "Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review," PharmacoEconomics - Open, Springer, vol. 4(3), pages 403-418, September.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      More about this item

      Statistics

      Access and download statistics

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:aphecp:v:6:y:2008:i:4:p:231-246. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.